JP5474768B2 - 臨床的に潜伏性の微生物を殺傷するための4−(ピロリジン−1−イル)キノリン化合物の使用 - Google Patents

臨床的に潜伏性の微生物を殺傷するための4−(ピロリジン−1−イル)キノリン化合物の使用 Download PDF

Info

Publication number
JP5474768B2
JP5474768B2 JP2010507981A JP2010507981A JP5474768B2 JP 5474768 B2 JP5474768 B2 JP 5474768B2 JP 2010507981 A JP2010507981 A JP 2010507981A JP 2010507981 A JP2010507981 A JP 2010507981A JP 5474768 B2 JP5474768 B2 JP 5474768B2
Authority
JP
Japan
Prior art keywords
methyl
compound
phenylpyrrolidin
formula
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010507981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527346A5 (enExample
JP2010527346A (ja
Inventor
ベスウィック,マンディ,クリスティン
クランプ,スーザン,マリー
フー,ヤンミン
パリン,トーマス,デビッド
ダイク,ヘーゼル,ジョアン
コーツ,アンソニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helperby Therapeutics Ltd
Original Assignee
Helperby Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0709489A external-priority patent/GB0709489D0/en
Priority claimed from GB0807591A external-priority patent/GB0807591D0/en
Application filed by Helperby Therapeutics Ltd filed Critical Helperby Therapeutics Ltd
Publication of JP2010527346A publication Critical patent/JP2010527346A/ja
Publication of JP2010527346A5 publication Critical patent/JP2010527346A5/ja
Application granted granted Critical
Publication of JP5474768B2 publication Critical patent/JP5474768B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D345/00Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010507981A 2007-05-17 2008-05-16 臨床的に潜伏性の微生物を殺傷するための4−(ピロリジン−1−イル)キノリン化合物の使用 Expired - Fee Related JP5474768B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0709489.9 2007-05-17
GB0709489A GB0709489D0 (en) 2007-05-17 2007-05-17 New use
GB0807591.3 2008-04-25
GB0807591A GB0807591D0 (en) 2008-04-25 2008-04-25 New use
PCT/GB2008/001694 WO2008142384A1 (en) 2007-05-17 2008-05-16 Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms

Publications (3)

Publication Number Publication Date
JP2010527346A JP2010527346A (ja) 2010-08-12
JP2010527346A5 JP2010527346A5 (enExample) 2011-06-30
JP5474768B2 true JP5474768B2 (ja) 2014-04-16

Family

ID=39672613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010507981A Expired - Fee Related JP5474768B2 (ja) 2007-05-17 2008-05-16 臨床的に潜伏性の微生物を殺傷するための4−(ピロリジン−1−イル)キノリン化合物の使用

Country Status (20)

Country Link
US (1) US8759348B2 (enExample)
EP (1) EP2182950B8 (enExample)
JP (1) JP5474768B2 (enExample)
KR (1) KR101599384B1 (enExample)
CN (1) CN101795688B (enExample)
AU (1) AU2008252636B2 (enExample)
BR (1) BRPI0811745B1 (enExample)
CA (1) CA2684692C (enExample)
DK (1) DK2182950T3 (enExample)
ES (1) ES2637999T3 (enExample)
HR (1) HRP20171553T1 (enExample)
HU (1) HUE034298T2 (enExample)
IL (1) IL201392A (enExample)
MX (1) MX2009012390A (enExample)
NZ (1) NZ580625A (enExample)
PL (1) PL2182950T3 (enExample)
PT (1) PT2182950T (enExample)
RU (1) RU2520766C2 (enExample)
SI (1) SI2182950T1 (enExample)
WO (1) WO2008142384A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021191791A (ja) * 2017-12-18 2021-12-16 アンセラ セラピューティクス インコーポレイテッドAnsella Therapeutics, Inc. 状態を予防及び治療するための組成物及び方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010095522A (ja) * 2008-09-19 2010-04-30 Sumitomo Chemical Co Ltd 植物病原菌による植物病害を防除又は予防するための農業用組成物
CN102933212B (zh) * 2010-03-30 2015-07-22 赫尔普百治疗有限公司 组合及应用
MX2012013127A (es) * 2010-05-13 2012-11-30 Amgen Inc Compuestos heteroariloxiheterociclilo como inhibidores pde10.
SI2600869T1 (sl) 2010-08-05 2021-03-31 Helperby Therapeutics Limited Kombinacija spojine pirolokinolin in beta-laktamskega protimikrobnega sredstva, mupirocina in klorheksidina
GB201013207D0 (en) 2010-08-05 2010-09-22 Helperby Therapeutics Ltd Novel combination
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
US20180214440A1 (en) 2015-04-11 2018-08-02 Helperby Therapeutics Limited Oral composition
WO2017027768A1 (en) * 2015-08-13 2017-02-16 The Broad Institute, Inc. Compositions and methods for treating tuberculosis
GB201518969D0 (en) 2015-10-27 2015-12-09 Helperby Therapeutics Ltd Triple combination
US11253511B2 (en) 2016-01-04 2022-02-22 The Johns Hopkins University Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)
KR102665309B1 (ko) * 2016-10-27 2024-05-10 주식회사 엘지생활건강 코디세핀을 포함하는 구강질환 예방 또는 치료용 조성물
GB201703898D0 (en) 2017-03-10 2017-04-26 Helperby Therapeautics Ltd Method
RU2664177C1 (ru) * 2017-08-07 2018-08-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) Способ лечения абсцедирующих фурункулов верхней и нижней зон лица
JP7269917B2 (ja) * 2017-08-17 2023-05-09 イケナ オンコロジー, インコーポレイテッド Ahr阻害剤およびその使用
CN110897032B (zh) * 2019-11-19 2025-10-14 华南理工大学 一种发酵饲料蛋白及其制备方法与应用
RU2758056C2 (ru) * 2019-11-21 2021-10-26 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Препарат для лечения отитов бактериальной и грибковой этиологии у собак
CN111544599B (zh) * 2020-07-10 2020-12-01 有术肌肤管理(深圳)有限公司 一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途
KR102461715B1 (ko) * 2020-10-12 2022-11-02 대한민국 항균 및 항진균 활성을 나타내는 신균주 페니실리움 비세티 및 이의 용도
CN114831924A (zh) * 2021-03-17 2022-08-02 武汉恒信源药业有限公司 一种乌洛托品及其化合物的阴道局部给药制剂及用途
CN113528388A (zh) * 2021-07-19 2021-10-22 海南大学 珊瑚共生链霉菌、发酵生产放线菌素d的方法及应用
CA3237199A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
EP1382603B1 (en) * 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
KR100621287B1 (ko) * 2001-05-21 2006-09-13 에프. 호프만-라 로슈 아게 신경 펩타이드 y 수용체에 대한 리간드로서의 퀴놀린유도체
US6787558B2 (en) * 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
EP1451156A4 (en) * 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
WO2003066055A1 (en) * 2002-02-04 2003-08-14 F. Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
CN1678586A (zh) 2002-06-27 2005-10-05 舍林股份公司 取代的喹啉ccr5受体拮抗剂
EP1530495A2 (en) * 2002-08-19 2005-05-18 Avi Elbaz Proprioceptive/kinesthetic apparatus and method
WO2004035569A2 (de) * 2002-10-10 2004-04-29 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
DE102004041163A1 (de) * 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
GB0522715D0 (en) * 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021191791A (ja) * 2017-12-18 2021-12-16 アンセラ セラピューティクス インコーポレイテッドAnsella Therapeutics, Inc. 状態を予防及び治療するための組成物及び方法
JP7502242B2 (ja) 2017-12-18 2024-06-18 アンセラ セラピューティクス インコーポレイテッド 状態を予防及び治療するための組成物及び方法
US12201607B2 (en) 2017-12-18 2025-01-21 Ansella Therapeutics, Inc. Compositions and methods for preventing and treating conditions

Also Published As

Publication number Publication date
CA2684692C (en) 2016-07-05
DK2182950T3 (da) 2017-11-06
CN101795688A (zh) 2010-08-04
CN101795688B (zh) 2015-05-20
HUE034298T2 (en) 2018-02-28
MX2009012390A (es) 2010-06-23
RU2520766C2 (ru) 2014-06-27
RU2009146828A (ru) 2011-06-27
EP2182950A1 (en) 2010-05-12
US8759348B2 (en) 2014-06-24
KR20100021476A (ko) 2010-02-24
ES2637999T3 (es) 2017-10-18
JP2010527346A (ja) 2010-08-12
AU2008252636B2 (en) 2013-10-31
SI2182950T1 (en) 2018-01-31
NZ580625A (en) 2011-12-22
CA2684692A1 (en) 2008-11-27
EP2182950B1 (en) 2017-07-19
WO2008142384A1 (en) 2008-11-27
IL201392A0 (en) 2010-05-31
HRP20171553T1 (hr) 2017-12-15
PT2182950T (pt) 2017-09-11
US20100305065A1 (en) 2010-12-02
BRPI0811745B1 (pt) 2019-06-04
EP2182950B8 (en) 2017-08-23
AU2008252636A1 (en) 2008-11-27
KR101599384B1 (ko) 2016-03-03
PL2182950T3 (pl) 2018-01-31
BRPI0811745A2 (pt) 2014-11-11
IL201392A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
JP5474768B2 (ja) 臨床的に潜伏性の微生物を殺傷するための4−(ピロリジン−1−イル)キノリン化合物の使用
JP5542336B2 (ja) 臨床的に潜伏性の微生物を死滅させるピロロキノリン化合物の使用
JP5559541B2 (ja) 局所製剤
WO2008117079A1 (en) Antimicrobial compounds based upon 4-aminoquinoline
HK1140146B (en) Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
HK1140146A (en) Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
MX2008006079A (en) Use of pyrroloquinoline compounds to kill clinically latent microorganisms

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20100630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130814

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140205

R150 Certificate of patent or registration of utility model

Ref document number: 5474768

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees